MTOR and tuberous sclerosis: A system medicine approach continues to contribute to advances in the development of biomarkers and therapies for TSC and has led to improved targeted treatments (e.g., mTOR inhibitors and gene therapy), tailored ASM selection, and advances in epilepsy surgery (67).